Reduced risk of breast cancer mortality in women using postmenopausal hormone therapy: A Finnish nationwide comparative study

Menopause

Volumn 23, Issue 11, 2016, Pages 1199-1203

  Mikkola, Tomi S ^a,b   Savolainen Peltonen, Hanna ^a,b   Tuomikoski, Pauliina ^a   Hoti, Fabian ^c   Vattulainen, Pia ^c   Gissler, Mika ^d   Ylikorkala, Olavi ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b BIOMEDICUM HELSINKI   (Finland)

^c EPID Research Oy   (Finland)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Breast cancer; Estradiol; Mortality; Postmenopausal hormone therapy

Indexed keywords

ESTRADIOL; ESTROGEN; GESTAGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER RISK; COMPARATIVE STUDY; FEMALE; FOLLOW UP; GROUPS BY AGE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MORTALITY RISK; RISK REDUCTION; BREAST TUMOR; EPIDEMIOLOGY; ESTROGEN THERAPY; FINLAND; MIDDLE AGED; MORTALITY; POSTMENOPAUSE; PROCEDURES; RISK FACTOR;

AGED; BREAST NEOPLASMS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FINLAND; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PROGESTINS; RISK FACTORS;

EID: 84980006479     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0000000000000698     Document Type: Article

References (41)

1. Shah NR, Borenstein J, Dubois RW. Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis. Menopause 2005;12:668-678.
2. Chlebowski RT, Anderson GL. Menopausal hormone therapy and cancer: changing clinical observations of target site specificity. Steroids 2014;90:53-59.
3. Prentice RL. Postmenopausal hormone therapy and the risks of coronary heart disease, breast cancer, and stroke. Semin Reprod Med 2014;32: 419-425.
4. Anderson GL, Chlebowski RT, Aragaki AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol 2012;13: 476-486.
5. Beral V, Reeves G, Bull D, Green J. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst 2011;103:296-305.
6. Magnusson C, Holmberg L, Nordén T, Lindgren A, Persson I. Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res Treat 1996;38:325-334.
7. Bonnier P, Bessenay F, Sasco AJ, et al. Impact of menopausal hormonereplacement therapy on clinical and laboratory characteristics of breast cancer. Int J Cancer 1998;79:278-282.
8. Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. J Am Med Assoc 1999;281:2091-2097.
9. Schuetz F, Diel IJ, Pueschel M, et al. Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy. Am J Obstet Gynecol 2007;196:342.e1-e9.
10. Reding KW, Doody DR, McTiernan A, et al. Age-related variation in the relationship between menopausal hormone therapy and the risk of dying from breast cancer. Breast Cancer Res Treat 2011;126:749-761.
11. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427.
12. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. J Am Med Assoc 2003;289:3243-3253.
13. Antoine C, Liebens F, Carly B, Pastijn A, Rozenberg S. Influence of HRT on prognostic factors for breast cancer: a systematic review after the Women's Health Initiative trial. Hum Reprod 2004;19:741-756.
14. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-1593.
15. Nanda K, Bastian LA, Schulz K. Hormone replacement therapy and the risk of death from breast cancer: a systematic review. Am J Obstet Gynecol 2002;186:325-334.
16. Chen W, Petitti DB, Geiger AM. Mortality following development of breast cancer while using oestrogen or oestrogen plus progestin: a computer record-linkage study. Br J Cancer 2005;93:392-398.
17. Pocobelli G, Newcomb PA, Li CI, Cook LS, Barlow WE, Weiss NS. Fatal breast cancer risk in relation to use of unopposed estrogen and combined hormone therapy. Breast Cancer Res Treat 2014;145: 439-447.
18. Newcomb PA, Egan KM, Trentham-Dietz A, et al. Prediagnostic use of hormone therapy and mortality after breast cancer. Cancer Epidemiol Biomarkers Prev 2008;17:864-871.
19. Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. J Am Med Assoc 2010;304:1684-1692.
20. Norman SA, Weber AL, Localio AR, et al. Hormone therapy and fatal breast cancer. Pharmacoepidemiol Drug Saf 2010;19:440-447.
21. Benkhadra K, Mohammed K, Al Nofal A, et al. Menopausal hormone therapy and mortality: a systematic review and meta-analysis. J Clin Endocrinol Metab 2015;100:4021-4028.
22. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol 2009;113:65-73.
23. Lyytinen H, Dyba T, Pukkala E, Ylikorkala O. Do the dose or route of administration of norethisterone acetate as a part of hormone therapy play a role in risk of breast cancer: national-wide case-control study from Finland. Int J Cancer 2010;127:185-189.
24. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol 2006;108: 1354-1360.
25. Mikkola TS, Tuomikoski P, Lyytinen H, et al. Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality. Menopause 2015;22:976-983.
26. Rothman KJ, Greenland S, eds. Modern Epidemiology. 2nd ed. Philadelphia, PA: Lippincott-Raven Publishers; 1998.
27. Breslow NE, Day NE. Statistical methods in cancer research. Volume II-The design and analysis of cohort studies. IARC Sci Publ 1987;82:1-406.
28. Marmot M, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. Lancet 2012;380:1778-1786.
29. Sarkeala T, Heinävaara S, Anttila A. Organised mammography screening reduces breast cancer mortality: a cohort study from Finland. Int J Cancer 2008;122:614-619.
30. Parvinen I, Heinävaara S, Anttila A, Helenius H, Klemi P, Pylkkänen L. Mammography screening in three Finnish residential areas: comprehensive population-based study of breast cancer incidence and incidencebased mortality 1976-2009. Br J Cancer 2015;112:918-924.
31. Lundström E, Wilczek B, Von Palffy Z, Söderqvist G, Von Schoultz B. Mammographic breast density during hormone replacement therapy: differences according to treatment. Am J Obstet Gynecol 1999;181:348-352.
32. Bremnes Y, Ursin G, Bjurstam N, Lund E, Gram IT. Different types of postmenopausal hormone therapy and mammographic density in Norwegian women. Int J Cancer 2007;120:880-884.
33. Kavanagh AM, Mitchell H, Giles GG. Hormone replacement therapy and accuracy of mammographic screening. Lancet 2000;355:270-274.
34. Coleman MP, Quaresma M, Berrino F, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 2008;9:730-756.
35. De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a populationbased study. Lancet Oncol 2014;15:23-34.
36. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol 1993;168:1473-1480.
37. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. J Am Med Assoc 2007;297:1465-1477.
38. Calle EE, Heath CW Jr, Coates RJ, et al. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-1059.
39. Manjer J, Malina J, Berglund G, Bondeson L, Garne JP, Janzon L. Increased incidence of small and well-differentiated breast tumours in post-menopausal women following hormone-replacement therapy. Int J Cancer 2001;92:919-922.
40. Daling JR, Malone KE, Doody DR, et al. Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years. Cancer Epidemiol Biomarkers Prev 2003;12:1175-1181.
41. Organisation for Economic Co-operation and Development (OECD). Health at a Glance 2015: OECD Indicators. Paris: OECD Publishing; 2015.